Edward Fiorentino
Known title: DirectorCIK: 0001666972
Associated companies
Transaction History
| SENS | ▲ Buy | Grant | 2,635 | $14K | 7/1/2026 | View on chart |
| SENS | ▲ Buy | Grant | 9,852 | $0 | 5/20/2026 | View on chart |
| SENS | ▲ Buy | Grant | 2,124 | $14K | 4/1/2026 | View on chart |
| SENS | ▲ Buy | Grant | 2,398 | $14K | 1/2/2026 | View on chart |
| SENS | ▲ Buy | Grant | 34,200 | $14K | 10/1/2025 | View on chart |
| SENS | ▲ Buy | Grant | 29,674 | $14K | 7/1/2025 | View on chart |
| SENS | ▲ Buy | Grant | 111,386 | $0 | 5/23/2025 | View on chart |
| SENS | ▲ Buy | Grant | 21,243 | $14K | 4/1/2025 | View on chart |
| SENS | ▲ Buy | Grant | 29,862 | $14K | 1/2/2025 | View on chart |
| SENS | ▲ Buy | Grant | 41,901 | $14K | 10/1/2024 | View on chart |
| SENS | ▲ Buy | Grant | 35,687 | $14K | 7/1/2024 | View on chart |
| SENS | ▲ Buy | Grant | 236,344 | $0 | 5/22/2024 | View on chart |
| SENS | ▲ Buy | Grant | 27,696 | $14K | 4/2/2024 | View on chart |
| SENS | ▲ Buy | Grant | 25,223 | $14K | 1/2/2024 | View on chart |
| SENS | ▲ Buy | Grant | 25,223 | $14K | 10/2/2023 | View on chart |
| SENS | ▲ Buy | Grant | 17,825 | $14K | 7/3/2023 | View on chart |
| SENS | ▲ Buy | Grant | 147,948 | $0 | 5/17/2023 | View on chart |
| SENS | ▲ Buy | Grant | 22,170 | $14K | 4/3/2023 | View on chart |
| SENS | ▲ Buy | Grant | 13,713 | $14K | 1/3/2023 | View on chart |
| SENS | ▲ Buy | Grant | 10,782 | $0 | 10/3/2022 | View on chart |
| SENS | ▲ Buy | Grant | 13,848 | $0 | 7/1/2022 | View on chart |
| SENS | ▲ Buy | Grant | 99,557 | $0 | 5/26/2022 | View on chart |
| SENS | ▲ Buy | Grant | 7,280 | $14K | 4/1/2022 | View on chart |
| SENS | ▲ Buy | Option Exercise | 83,900 | $45K | 3/11/2022 | View on chart |
| SENS | ▼ Sell | Open Market | 63,553 | $105K | 3/11/2022 | View on chart |
| SENS | ▲ Buy | Grant | 5,136 | $14K | 1/3/2022 | View on chart |
| SENS | ▲ Buy | Grant | 4,094 | $14K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Beta Bionics and Senseonics announce iLet-Eversense 365 integration
Beta Bionics and Senseonics announced a deal to integrate the iLet automated insulin delivery system with the Eversense 365 continuous glucose monitor. This partnership aims to provide a more seamless solution for patients managing diabetes. The news highlights a strategic move to combine two major technologies in the diabetes care market.
Beta Bionics and Senseonics announce iLet-Eversense 365 integration. Beta Bionics and Senseonics announced a deal to integrate the iLet automated insulin delivery system with the Eversense 365 continuous glucose monitor. This partnership aims to provide a more seamless solution for patients managing diabetes. The news highlights a strategic move to combine two major technologies in the diabetes care market.